[1] Moon AM, Singal AG, Tapper EB. Contemporary epidemiology of chronic liver disease and cirrhosis[J]. Clin Gastroenterol Hepatol, 2020,18(12):2650-2666. DOI: 10.1016/j.cgh.2019.07.060.
[2] Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis[J]. BMC Med, 2014,12:145. DOI: 10.1186/s12916-014-0145-y.
[3] Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis[J]. Age Ageing, 2019,48(1):16-31. DOI: 10.1093/ageing/afy169.
[4] Tandon P, Low G, Mourtzakis M, et al. A model to identify sarcopenia in patients with cirrhosis[J]. Clin Gastroenterol Hepatol, 2016,14(10):1473-1480.e3. DOI: 10.1016/j.cgh.2016.04.040.
[5] Tantai X, Liu Y, Yeo YH, et al. Effect of sarcopenia on survival in patients with cirrhosis: a meta-analysis[J]. J Hepatol, 2022,76(3):588-599. DOI: 10.1016/j.jhep.2021.11.006.
[6] Sinclair M, Gow PJ, Grossmann M, et al. Review article: sarcopenia in cirrhosis--aetiology, implications and potential therapeutic interventions[J]. Aliment Pharmacol Ther, 2016 ,43(7):765-777. DOI: 10.1111/apt.13549.
[7] Duarte-Rojo A, Ruiz-Margáin A, Montaño-Loza AJ, et al. Exercise and physical activity for patients with end-stage liver disease: improving functional status and sarcopenia while on the transplant waiting list[J]. Liver Transpl, 201,24(1):122-139. DOI: 10.1002/lt.24958.
[8] Paternostro R, Bardach C, Hofer BS, et al. Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension[J]. Liver Int, 2021,41(4):799-809. DOI: 10.1111/liv.14758.
[9] Lin SY, Wang YY, Chuang YH, et al. Skeletal muscle proteolysis is associated with sympathetic activation and TNF-α-ubiquitin-proteasome pathway in liver cirrhotic rats[J]. J Gastroenterol Hepatol, 2016,31(4):890-896. DOI: 10.1111/jgh.13159.
[10] Lin SY, Chen WY, Lee FY, et al. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha[J]. Am J Physiol Endocrinol Metab, 2005,288(3):E493-501. DOI: 10.1152/ajpendo.00186.2004.
[11] Beyer I, Mets T, Bautmans I. Chronic low-grade inflammation and age-related sarcopenia[J]. Curr Opin Clin Nutr Metab Care, 2012,15(1):12-22. DOI: 10.1097/MCO.0b013e32834dd297.
[12] Milan G, Romanello V, Pescatore F, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy[J]. Nat Commun, 2015,6:6670. DOI: 10.1038/ncomms7670.
[13] García PS, Cabbabe A, Kambadur R, et al. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting[J]. Anesth Analg, 2010,111(3):707-709. DOI: 10.1213/ANE.0b013e3181eac1c9.
[14] Hanai T, Shiraki M, Watanabe S, et al. Sarcopenia predicts minimal hepatic encephalopathy in patients with liver cirrhosis[J]. Hepatol Res, 2017,47(13):1359-1367. DOI: 10.1111/hepr.12873.
[15] Chang KV, Chen JD, Wu WT, et al. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis[J]. J Formos Med Assoc, 2019,118(4):833-842. DOI: 10.1016/j.jfma.2018.09.011.
[16] Mauro E, Crespo G, Martinez-Garmendia A, et al. Cystatin C and sarcopenia predict acute on chronic liver failure development and mortality in patients on the liver transplant waiting list[J]. Transplantation, 2020,104(7):e188-e198. DOI: 10.1097/TP.0000000000003222.
[17] Cho MR, Lee S, Song SK. A review of sarcopenia pathophysiology, diagnosis, treatment and future direction[J]. J Korean Med Sci, 2022,37(18):e146. DOI: 10.3346/jkms.2022.37.e146.
[18] Damas F, Phillips S, Vechin FC, et al. A review of resistance training-induced changes in skeletal muscle protein synthesis and their contribution to hypertrophy[J]. Sports Med, 2015 ,45(6):801-807. DOI: 10.1007/s40279- 015-0320-0.
[19] Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease[J]. J Hepatol, 2016,65(6):1232-1244. DOI: 10.1016/j.jhep.2016.07.040.
[20] 董欣,王小清,王秀华,等. 氧化应激在肌少症发生过程中作用的研究进展[J]. 中国老年学杂志,2022,42(3):744-748. DOI:10.3969/j.issn.1005-9202.2022.03.065.
[21] 王勤. 太极拳运动干预对肝硬化合并肌少症患者运动功能和生活质量的影响[D]. 郑州:郑州大学,2022.
[22] Aamann L, Dam G, Borre M, et al. Resistance training increases muscle strength and muscle size in patients with liver cirrhosis[J]. Clin Gastroenterol Hepatol, 2020,18(5):1179-1187.e6. DOI: 10.1016/j.cgh.2019.07.058.
[23] European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease[J]. J Hepatol, 2019,70(1):172-193. DOI: 10.1016/j.jhep.2018.06.024.
[24] Bunchorntavakul C, Reddy KR. Review article: malnutrition/sarcopenia and frailty in patients with cirrhosis[J]. Aliment Pharmacol Ther, 2020,51(1):64-77. DOI: 10.1111/apt.15571.
[25] Bischoff SC, Bernal W, Dasarathy S, et al. ESPEN practical guideline: Clinical nutrition in liver disease[J]. Clin Nutr, 2020,39(12):3533-3562. DOI: 10.1016/j.clnu.2020. 09.001.
[26] 宋晓婷,许文涛. «2021年美国肝病学会实践指导:肝硬化患者营养不良、衰弱和肌肉减少症»摘译[J]. 临床肝胆病杂志,2021,37(12):2787-2789. DOI:10.3969/j.issn. 1001-5256.2021.12.011.
[27] 曾欣,鲁益婷. 肝硬化患者的营养评估与干预[J]. 中华消化杂志,2023,43(4):257-261. DOI:10.3760/cma.j.cn311367- 20230206-00051.
[28] 王菁华,黄怡寒,金丹英,等. 个性化中医营养护理干预对乙型肝炎肝硬化腹水患者腹水消退情况和营养状况的影响[J]. 检验医学与临床,2023,20(2):261-265. DOI:10.3969/j.issn.1672-9455.2023.02.030.
[29] Berzigotti A, Albillos A, Villanueva C, et al. Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: the sportdiet study[J]. Hepatology, 2017,65(4):1293-1305. DOI: 10.1002/hep.28992.
[30] 付志鹏,郑盛,杨涓. 肝硬化患者营养评价方法研究进展[J]. 国际医药卫生导报,2023,29(23):3341-3344. DOI:10.3760/cma.j.issn.1007-1245.2023.23.005.
|